Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Short Stature

Short Stature

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Short Stature

6 trials tracked for Short Stature: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 84 citations.

6Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 2
  1. Phase 3 Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children Completed · 84 cited
  2. Phase 4 Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole Completed · 32 cited
  3. Phase 4 Growth Hormone and Endothelial Function in Children Completed
  4. Phase 3 Weekly Zinc Chelate Supplementation on Children's Growth Completed
  5. Phase 2 Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency Completed
  6. Phase 2 IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Short Stature: what the trials found

Clinical investigations have evaluated several pharmacological and nutritional interventions for short stature. Letrozole has been studied in a Phase 4 trial 1, and Genotropin was evaluated in a Phase 3 trial 3.

Zinc amino acid chelate demonstrated statistically significant improvements in the Height-for-Age Z-score (HAZ) from the end of supplementation to the end of the follow-up period (p<0.05) 4.

Recent results — preliminary, needs further review

  • Norditropin showed a range of outcomes for Height Standard Deviation Score and Height Velocity after three years of treatment, but these findings are not yet corroborated 5.
  • Increlex was evaluated in a Phase 2 trial regarding Height Standard Deviation Score, but results are not yet corroborated 6.

For the clinician treating this condition

  • Zinc amino acid chelate is associated with statistically significant improvements in Height-for-Age Z-scores (p<0.05) 4.
  • Letrozole and Genotropin have been evaluated in Phase 3 and 4 trials for short stature, though specific outcome metrics were not provided in the summary data [1, 3].

AI synthesis of 5 cited trials, updated Jul 18, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
A novel PTHLH nonsense variant is associated with brachydactyly type E and short stature
Diabetes & Endocrinology Sys. Review
A novel PTHLH nonsense variant is associated with brachydactyly type E and short stature New Genetic Variant Linked to Short Stature and Brachydactyly
This case report describes a mother-son pair with brachydactyly type E and short stature. The authors identify a novel heterozygous nonsense…
A new genetic finding helps doctors better understand why some children with brachydactyly type E also experience short stature.
Frontiers Jul 17, 2026